
|Videos|October 16, 2015
Significance of the RADIANT-4 Study for Advanced Nonfunctional NETs of Lung or Gastrointestinal Origin
Author(s)Jennifer Eads, MD
Jennifer Eads, MD, assistant professor of Medicine, senior clinical instructor of Medicine, Case Western University, reflects on the phase III RADIANT-4 study, which examined everolimus in advanced nonfunctional neuroendocrine tumors of lung or gastrointestinal origin.
Advertisement
Jennifer Eads, MD, assistant professor of Medicine, senior clinical instructor of Medicine, Case Western University, reflects on the phase III RADIANT-4 study, which examined everolimus in advanced nonfunctional neuroendocrine tumors of lung or gastrointestinal origin.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5

























